Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis

Rheumatology

Volumn 47, Issue 3, 2008, Pages 249-255

  Wessels, J A M ^a   Huizinga, T W J ^a   Guchelaar, H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Methotrexate; Molecular mechanisms of action; Pharmacology; Rheumatoid arthritis

Indexed keywords

ADENOSINE; CELL ADHESION MOLECULE; CYTOKINE; GLUTATHIONE; INTERCELLULAR ADHESION MOLECULE 1; METHOTREXATE; NUCLEOTIDE; PLACEBO; PREDNISOLONE; REACTIVE OXYGEN METABOLITE;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG RESPONSE; EVIDENCE BASED MEDICINE; GENETIC VARIABILITY; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; MITOSIS INHIBITION; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ADENOSINE; ANIMALS; APOPTOSIS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLIC ACID; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; MALE; METHOTREXATE; REACTIVE OXYGEN SPECIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 39449121672     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem279     Document Type: Review

References (63)

1. Pincus T, Ferraccioli G, Sokka T et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: Updating a 1983 review. Rheumatology 2002;41:1346-56.
2. Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: The first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006;54:1366-77.
3. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004;50:1370-82.
4. van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum, 2001;44:1515-24.
5. Cutolo M, Sulli A, Pizzomi C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001;60:729-35.
6. Cronstein BN. Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005;57:163-72.
7. Phillips DC, Woollard KJ, Griffiths HR. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 2003;138:501-11.
8. Herman S, Zurgil N, Langevitz P, Ehrenfeld M, Deutsch M. The induction of apoptosis by methotrexate in activated lymphocytes as indicated by fluorescence hyperpolarization: A possible model for predicting methotrexate therapy for rheumatoid arthritis patients. Cell Struct Funct 2003;28:113-22.
9. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 2005;54:273-80.
10. Herman S, Zurgil N, Langevitz P, Ehrenfeld M, Deutsch M. The immunosuppressive effect of methotrexate in active rheumatoid arthritis patients vs. its stimulatory effect in nonactive patients, as indicated by cytometric measurements of CD4+ T cell subpopulations. Immunol Invest 2004;33:351-62.
11. Huang CC, Hsu PC, Hung YC et al. Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production. Apoptosis 2005;10:895-907.
12. Hsu PG, Hour TC, Liao YF et al. Increasing ornithine decarboxylase activity is another way of prolactin preventing methotrexate-induced apoptosis: Crosstalk between ODC and BCL-2. Apoptosis 2006;11:389-99.
13. Quemeneur L, Gerland LM, Flacher M, Ffrench M, Revillard JP, Genestier L. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol 2003;170:4986-95.
14. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002;128:255-66.
15. Winter-Vann AM, Kamen BA, Bergo MO et al. Targeting Ras signaling through inhibition of carboxyl methylation: An unexpected property of methotrexate. Proc Natl Acad Sci USA 2003;100:6529-34.
16. Moller B, Kukoc-Zivojnov N, Okamgba S et al. Folinic acid antagonizes methotrexate-induced differentiation of monocyte progenitors. Rheumatol Int 2002;22:60-7.
17. Singh R, Fouladi-Nashta AA, Li D, Halliday N, Barrett DA, Sinclair KD. Methotrexate-induced differentiation in colon cancer cells is primarily due to purine deprivation. J Cell Biochem 2006;99:146-55.
18. Swierkot J, Miedzybrodzki R, Szymaniec S, Szechinski J. Activation dependent apoptosis of peripheral blood mononuclear cells from patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 2004;63:599-600.
19. Hasko G, Cronstein BN. Adenosine: An endogenous regulator of innate immunity. Trends Immunol 2004;25:33-9.
20. Montesinos MC, Desai A, Delano D et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003;48:240-7.
21. Delano DL, Montesinos MC, Desai A et al. Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation. Arthritis Rheum 2005;52:2567-75.
22. Nakamachi Y, Koshiba M, Nakazawa T et al. Specific increase in enzymatic activity of adenosine deaminase 1 in rheumatoid synovial fibroblasts. Arthritis Rheum 2003;48:668-74.
23. van Ede AE, Laan RF, De Abreu RA, Stegeman AB, van de Putte LB. Purine enzymes in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 2002;61:1060-4.
24. Riksen NP, Barrera P, van den Broek PH, van Riel PL, Smits P, Rongen GA. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis 2006;65:465-70.
25. Ralph JA, McEvoy AN, Kane D, Bresnihan B, FitzGerald O, Murphy EP. Modulation of orphan nuclear receptor NURR1 expression by methotrexate in human inflammatory joint disease involves adenosine A2A receptor-mediated responses. J Immunol 2005;175:555-65.
26. Dolezalova P, Krijt J, Chladek J, Nemcova D, Hoza J. Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis. Rheumatology 2005;44:74-9.
27. Montesinos MC, Takedachi M, Thompson LF, Wilder TF, Fernandez P, Cronstein BN. The antiinflammatory mechanism ot methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5′-nucleotidase - findings in a study of ecto-5′-nucleotidase gene-deficient mice. Arthritis Rheum 2007;56:1440-5.
28. Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeiner evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000;43:656-63.
29. Nesher G, Mates M, Zevin S. Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 2003;48:571-2.
30. Benito-Garcia E, Heller JE, Chibnik LB et al. Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J Rheumatol 2006;33:1275-81.
31. Gerards AH, oe Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. Inhibition of cytokine production by methatrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 2003;42:1189-96.
32. de Lathouder S, Gerardo AH, Dijkmans BA, Aarden LA. Two inhibitors of DNA-syntheses lead to inhibition of cytokine production As a different mechanism. Nucleos Nucleot Nucl 2004;23:1089-100.
33. Kraan MC, Smests TJ, van Loon MJ, Breadveld PC, Dijkmans BA, Tak PP. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 2004;639:1056-61.
34. de Lathouder S, Gerards AH, de Groot ER, Valkhof M, Aarden LA. Mycophenolic acid and methotrexate inhibit lymphocyte, cytokine production via different mechanisms. Eur Cytokine Netw 2002;13:317-23.
35. Seitz M, Valbracht J, Quach J, Lotz M. Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic: THP-1 cells through distinct transcriptional and posttranslational mechanisms. J Clin Immunol 2003;23:477-84.
36. Cutolo M, Sulli A, Craviotto, C et al. Antiproliferative-antiinflammatory effects of methotrexate and sex hormones on cultured differentiating myeloid monocytic cells (THP-1). Ann N Y Acad Sci 2002;966:232-7.
37. Giacomelli R, Cipriani P, Matucci CM et al. Combination therapy with cyclosporine and-methotrexate in patients with early rheumatoid arthritis soon inhibits TNF-alpha production without decreasing TNFalpha mRNA levels. An in vivo and in vitro study. Clin Exp Rheumatol 2002;20:365-72.
38. Aggarwal A, Misra R. Methotrexate inhibits interleukin-6 production in patient with juvenile rheumatoid arthritis. Rheumatol Int 2003;23:134-7.
39. Miranda-Carus ME, Balsa A, Benito-Miguel M, Perez dA, Martin-Mola E. IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: Effect of methotrexate. J Immunol 2004;173:1463-76.
40. Seitz M, Zwicker M, Villiger PM. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patents with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate. J Rheumatol 2003;30:28-35.
41. Wijngaarden S, van Roon JA, van do Winkel JG, Bijlsma JW, Lafeber FP. Down-regulation of activating Fcgamma receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment. Rheumatology 2005;44:729-34.
42. Bunescu A, Seideman P, Lenkei R, Levin K, Egberg N. Enhanced Fcgamma receptor 1, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: Interaction with platelets. J Rheumatol 2004;31:2347-55.
43. Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappaB activation through inhibition, of IkappaBalpha phosphorylation and degradation. J Immunol 2001; 167:29111-20.
44. Parker A, Izmailova, ES, Narang J et al. Peripheral blood expression of nuclear factor-kappaB-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol 20007;34:1817-22.
45. Szekanecz Z, Koch AE. Cell-cell interactions in synovitis. Endothelial cells and immune cell migration Arthritis Res 2000;2:368-73.
46. Johnston A, Gudjonsson JE, Sigmundsdottir W, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005, 114:154-63.
47. Kane D, Gogarty M, O'leary J et al. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with mothotrexate. Arthritis Rheum 2004;50:3286-95.
48. Sigmundsdottir H, Johnston A, Gudjonsson JE, Valdimarsson H. Differential effects of interleukin 12 and interleukin 10 on superantigen-induced expression of cutaneous. lymphocyte-associated antigen (CLA) and alphaEbeta7 integrin (CD103) by CD8+ T cells. Clin Immunol 2004;111:119-25.
49. Dahlman-Ghozlan K, Ortonne JP, Heilborn JD, Stephansson E. Altered tissue expression pattern of cell adhesion molecules, ICAM-1, E-selectin and VCAM-1, in bullous pemphigoid during methotrexate therapy. Exp Dermatol 2004;13:65-9.
50. Yamasaki E, Soma Y, Kawa Y, Mizoguchi M. Methotrexate inhibits proliferation and regulation of the expression of intercellular adhesion molecle-1 and vascular cell adhesion molecule-1 by cultured human umbilical vein endothelial cells. Br J Dermatol 2003; 149:30-8.
51. Yazici AC, Tursen U, Apa DD, et al. The changes in expression of ICAM-3,Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment. Arch Dermatol Res 2005;297:249-55.
52. Dessein PH, Joffe BI. Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. Clin Ex Rhoumatol 2006;24:161-7.
53. Rau R, Herborn G, Menninger H, Sangha O. Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients: Rheumatology 2002; 11: 196-204.
54. Lee CK, Lee EY, Chung SM, Mun SH, Yoo B,. Moon HB, Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum 2004;50:3831-43.
55. Minaur NJ, Jefferiss C, Bhalla AK, Beresford JN. Mothotrexate in the treatment of rheumatoid arthritis I. In vitro effects on cells of the osteoblast lineage. Rheumatology 2002;41:735-40.
56. Minaur NJ, Kounali D, Vedi S, Compston JE, Beresford JN, Bhalla AK. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology 2002;41:741-9.
57. Yoshida M, Kanno Y, Ishisaki et al. Methotrexate suppresess inflammatory agonist induced interleukin 6 syntheses in osteoblasts. J Rheumatol 2005;32:787-95.
58. Walsh DA. Angiogenesis and arthritis. Rheumatology 1999;38:103-12.
59. Fiehn C, Wunder A, Krienke S, Max R, Ho AD, Moehler T. Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate. Rheumatol Int 2005;25:108-13.
60. Kusabe T, Waguri-Nagaya Y, Tanikawa T et al. The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/ platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes. Rheumatol Int 2005;25:625-30.
61. Solomon S, Masilamani M, Mohanty S, Schwab JE, Boneberg EM, Iliges H. Generation of three-dimensional pannus-like tissues in vitro from single cell suspensions of synovial fluid cells from arthritis patients. Rheumatol Int 2004;24:71-6.
62. Lange F, Bajtner E, Rintisch C, Nandakumar KS, Sack U, Holmdahl R. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. Ann Rheum Dis 2005;64:599-605.
63. Cheok MH, Yang W, Pui CH et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cell Nat Genet 2003;34.85-90.